OUR PURPOSE IS SIMPLE:
Patients fighting chronic diseases are often denied access to life-saving treatments.
ICERWatch gives patients a voice to fight back.
We have an important message for ICER: Patients are not a number. Patients living with depression and multiple sclerosis have the same right to access treatments as anyone else.
An obscure health care cost evaluator could deliver a devastating blow to patients living with multiple sclerosis this week, as it evaluates a promising new
As the draft report notes, “the quality of life outcomes for the phase 3 trials have not yet been published. It is [therefore] challenging to fully evaluate the impact of these therapies without placebo-controlled assessments of the change in quality of life.” Given the reality of such limited data – particularly about patient perspectives and quality – we believe it is too early for ICER to conduct this assessment.
When Kate was diagnosed with cervical cancer, her doctors were optimistic. The right treatment could mean that Kate “could heal and live a long, healthy
With the backing of multi-billion-dollar insurance companies, ICER is conducting an analysis of a treatment for secondary progressive multiple sclerosis.
The debate over former vice presidential candidate Sarah Palin’s inaccurately named “death panels” has come to Massachusetts. The debate centers on a measure of cost-effectiveness